Inventor
NADLER STEVEN G
US27 patents
⚠️ This page may combine multiple inventors who share the name “NADLER STEVEN G”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BRISTOL MYERS SQUIBB CO
18 patentsUS5962415AOct 5, 1999
Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
BRISTOL MYERS SQUIBB CO28 citations92
US9228018B2Jan 5, 2016
Antibody polypeptides that antagonize CD40L
BRISTOL MYERS SQUIBB CO11 citations91
US8895010B2Nov 25, 2014
Antibody polypeptides that antagonize CD40L
BRISTOL MYERS SQUIBB CO24 citations91
US5877282AMar 2, 1999
Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
BRISTOL MYERS SQUIBB CO47 citations89
US10919965B2Feb 16, 2021
Compositions monovalent for CD28 binding and methods of use
BRISTOL MYERS SQUIBB CO3 citations83
US9908937B2Mar 6, 2018
Compositions monovalent for CD28 binding and methods of use
BRISTOL MYERS SQUIBB CO5 citations83
US9765150B2Sep 19, 2017
Antibody polypeptides that antagonize CD40L
BRISTOL MYERS SQUIBB CO5 citations82
US8981072B2Mar 17, 2015
Nucleic acids encoding antibody polypeptides that antagonize CD40L
BRISTOL MYERS SQUIBB CO8 citations82
US7244573B2Jul 17, 2007
Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
BRISTOL MYERS SQUIBB CO14 citations82
US6869956B2Mar 22, 2005
Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
BRISTOL MYERS SQUIBB CO9 citations72
US10196451B2Feb 5, 2019
Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L
BRISTOL MYERS SQUIBB CO1 citations71
US11267888B2Mar 8, 2022
Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
BRISTOL MYERS SQUIBB CO2 citations67
US6730302B1May 4, 2004
Intracellular targeted delivery of compounds by 70 kD heat shock protein
BRISTOL MYERS SQUIBB CO9 citations66
US12012452B2Jun 18, 2024
Compositions monovalent for CD28 binding and methods of use
BRISTOL MYERS SQUIBB CO0 citations61
US11180567B2Nov 23, 2021
Antibody polypeptides that antagonize CD40L
BRISTOL MYERS SQUIBB CO0 citations61
US11912769B2Feb 27, 2024
Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28
BRISTOL MYERS SQUIBB CO0 citations56
US7442554B2Oct 28, 2008
Compositions and methods involving glucocorticoid receptor site II
BRISTOL MYERS SQUIBB CO0 citations52
US7670785B2Mar 2, 2010
Polynucleotides and polypeptides associated with the development of rheumatoid arthritis
BRISTOL MYERS SQUIBB CO0 citations50
Aro Biotherapeutics Company
6 patentsUS11628222B2Apr 18, 2023
CD71 binding fibronectin type III domains
Aro Biotherapeutics Company5 citations82
US11781138B2Oct 10, 2023
FN3 domain-siRNA conjugates and uses thereof
Aro Biotherapeutics Company4 citations71
US12239710B2Mar 4, 2025
FN3 domain-siRNA conjugates and uses thereof
Aro Biotherapeutics Company2 citations70
US12037379B2Jul 16, 2024
CD71 binding fibronectin type III domains
Aro Biotherapeutics Company2 citations68
US12589159B2Mar 31, 2026
CD71 binding fibronectin type III domains
Aro Biotherapeutics Company0 citations59
US12491255B2Dec 9, 2025
EPCAM binding fibronectin type III domains
Aro Biotherapeutics Company0 citations59
MCKINNON MURRAY
3 patentsUS9085629B2Jul 21, 2015
Compositions monovalent for CD28 binding and methods of use
MCKINNON MURRAY18 citations90
US8454959B2Jun 4, 2013
Compositions monovalent for CD28 binding and methods of use
MCKINNON MURRAY23 citations90
US8168759B2May 1, 2012
Compositions monovalent for CD28 binding and methods of use
MCKINNON MURRAY21 citations90